Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PENDLETON WICKERSHAM

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1053380048
CMS profile
229044
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$14,265.50

152 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PENDLETON WICKERSHAM

NPI 1053380048 · CMS profile ID 229044

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1053380048?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PENDLETON WICKERSHAM, NPI 1053380048, CMS profile ID 229044. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1053380048?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). PENDLETON WICKERSHAM, NPI 1053380048, CMS profile ID 229044. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1053380048?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
PENDLETON WICKERSHAM, NPI 1053380048, CMS profile ID 229044, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1053380048?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

152 matching records · $14,265.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 152 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 152.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $50.0009/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184509220 CMS
E.R. Squibb & Sons, L.L.C. $449.4309/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1184509222 CMS
E.R. Squibb & Sons, L.L.C. $30.0009/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184509224 CMS
E.R. Squibb & Sons, L.L.C. $65.0009/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184509228 CMS
E.R. Squibb & Sons, L.L.C. $311.3709/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1184509226 CMS
Janssen Biotech, Inc. $5.7709/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175133304 CMS
Novartis Pharmaceuticals Corporation $16.1909/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200496388 CMS
GlaxoSmithKline, LLC. $13.2408/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190919359 CMS
Janssen Biotech, Inc. $6.9808/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175138440 CMS
Novartis Pharmaceuticals Corporation $23.6408/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200496386 CMS
Amgen Inc. $9.7608/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227054988 CMS
GlaxoSmithKline, LLC. $16.0308/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190620624 CMS
Janssen Biotech, Inc. $5.1308/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175130460 CMS
AstraZeneca Pharmaceuticals LP $16.4908/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206819553 CMS
Novartis Pharmaceuticals Corporation $23.2308/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200496384 CMS
ABBVIE INC. $7.8908/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204743788 CMS
ABBVIE INC. $12.1108/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204743784 CMS
Janssen Biotech, Inc. $15.1608/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175136957 CMS
Amgen Inc. $17.6608/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228657761 CMS
Amgen Inc. $14.3407/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227055006 CMS
AstraZeneca Pharmaceuticals LP $18.1307/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207246561 CMS
Janssen Biotech, Inc. $5.6007/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175140008 CMS
Amgen Inc. $10.8807/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227055022 CMS
Novartis Pharmaceuticals Corporation $18.9307/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200496382 CMS
Almatica Pharma LLC $22.9907/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1209938259 CMS
Amgen Inc. $13.2007/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227054986 CMS
Janssen Biotech, Inc. $4.9707/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175134271 CMS
Amgen Inc. $17.0007/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228657765 CMS
GlaxoSmithKline, LLC. $17.5707/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190977471 CMS
ABBVIE INC. $17.9207/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204743781 CMS
Janssen Biotech, Inc. $9.7607/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175130325 CMS
Novartis Pharmaceuticals Corporation $18.4006/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200496380 CMS
Janssen Biotech, Inc. $16.2006/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175129211 CMS
Janssen Biotech, Inc. $21.7306/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175132319 CMS
Janssen Biotech, Inc. $17.4506/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175139649 CMS
AstraZeneca Pharmaceuticals LP $15.2906/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206232030 CMS
AstraZeneca Pharmaceuticals LP $80.2306/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206253136 CMS
Janssen Biotech, Inc. $5.3606/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175140588 CMS
Amgen Inc. $10.5506/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227055030 CMS
ABBVIE INC. $7.6305/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204743778 CMS
GlaxoSmithKline, LLC. $15.8005/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190640267 CMS
Janssen Biotech, Inc. $6.7005/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175128049 CMS
Janssen Biotech, Inc. $6.9805/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175130022 CMS
Amgen Inc. $4.9505/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227054998 CMS
Janssen Biotech, Inc. $6.0405/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175128507 CMS
Novartis Pharmaceuticals Corporation $30.9205/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200496378 CMS
GlaxoSmithKline, LLC. $14.7905/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190413575 CMS
Amgen Inc. $14.2705/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227055020 CMS
E.R. Squibb & Sons, L.L.C. $5.6005/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184509152 CMS
ABBVIE INC. $11.9005/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204743774 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $130,665.43 332
PY2020 $86,488.68 252
PY2021 $69,223.45 277
PY2022 $219,281.28 412
PY2023 $172,786.95 353
PY2024 $260,849.57 397
PY2025 $14,265.50 152

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $144,561.93 25
PY2024 Principal investigator $278,031.63 41
PY2023 Principal investigator $337,192.42 33
PY2022 Recipient $90.00 1
PY2022 Principal investigator $192,711.61 110
PY2021 Principal investigator $202,804.86 96
PY2020 Recipient $1,502.00 1
PY2020 Principal investigator $34,900.22 35
PY2019 Recipient $35,280.00 1
PY2019 Principal investigator $50,584.11 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

25 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca UK Limited $1,500.00 12/22/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS LLC
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185554534
Principal investigator 1 ABBVIE INC. $2,221.55 11/04/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202520177
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,043.34 10/22/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246431148
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,352.80 10/13/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246431154
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,750.00 10/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
INSPIRE LTE study No dispute reported 06/30/2026 1246431150
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,750.00 09/11/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246431152
Principal investigator 1 ABBVIE INC. $2,178.35 07/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202494903
Principal investigator 1 ABBVIE INC. $3,593.25 05/06/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202481233
Principal investigator 1 Amgen Inc. $45,447.59 04/30/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246640387
Principal investigator 1 ABBVIE INC. $2,568.50 04/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202470554
Principal investigator 1 AstraZeneca UK Limited $1,120.00 03/21/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185554532
Principal investigator 1 ABBVIE INC. $2,360.60 03/06/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202457111
Principal investigator 1 ABBVIE INC. $5,000.00 02/18/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202452173
Principal investigator 1 ABBVIE INC. $175.50 02/18/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202452182
Principal investigator 1 Eli Lilly and Company $1,309.80 02/10/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187879503
Principal investigator 1 ABBVIE INC. $2,403.80 02/06/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202447143
Principal investigator 1 ABBVIE INC. $6,375.00 01/27/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202441274
Principal investigator 1 Eli Lilly and Company $15,858.00 01/21/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187878211
Principal investigator 1 ABBVIE INC. $40.50 01/14/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202438249
Principal investigator 1 ABBVIE INC. $1,917.00 01/14/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202438253
Principal investigator 1 ABBVIE INC. $600.00 01/14/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202438261
Principal investigator 1 ABBVIE INC. $600.00 01/14/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202438268
Principal investigator 1 ABBVIE INC. $1,440.00 01/14/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202438273
Principal investigator 1 AstraZeneca UK Limited $34,778.00 01/03/2025 Non-covered Recipient Entity
FLOURISH RESEARCH, SAN ANTONIO
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185554536
Principal investigator 1 ABBVIE INC. $2,178.35 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202433692